Comparative Effectiveness of First-Line Treatments for Castration-Resistant Prostate Cancer: A Large-Scale Retrospective Study in Japan
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Enzalutamide (ENZ) shows better overall survival than abiraterone acetate (ABI) as a first-line treatment for castration-resistant prostate cancer (CRPC). Sequential ABI-ENZ therapy may also improve overall survival in CRPC patients.
Area Of Science
- Oncology
- Urology
Background
- Prostate cancer is a leading cause of cancer death globally, with high mortality in certain populations.
- Castration-resistant prostate cancer (CRPC) presents a significant clinical challenge due to limited survival.
- Effective treatment strategies for CRPC are urgently needed.
Purpose Of The Study
- To evaluate the comparative effectiveness of first-line treatments for CRPC in a large Japanese patient cohort.
- To assess the efficacy of enzalutamide (ENZ), abiraterone acetate (ABI), and docetaxel (DOC).
- To investigate the outcomes of sequential abiraterone acetate followed by enzalutamide therapy.
Main Methods
- Retrospective analysis of a Japanese hospital database (April 2008 - December 2022).
- Inclusion of 18,924 CRPC patients treated with first-line ENZ, ABI, or DOC.
- Analysis of overall survival (OS), treatment efficacy in bone metastasis patients, and time to treatment failure for sequential therapy.
Main Results
- Enzalutamide (ENZ) demonstrated prolonged overall survival (OS) compared to abiraterone acetate (ABI) in the overall CRPC population (HR: 0.903, p < 0.003).
- No significant difference in treatment efficacy between ABI and ENZ was observed in patients with bone metastases.
- Sequential ABI-ENZ therapy showed no significant difference in time to treatment failure but was associated with improved OS.
Conclusions
- Enzalutamide (ENZ) appears to be the most effective first-line treatment for Japanese CRPC patients based on OS outcomes.
- Abiraterone acetate (ABI)-Enzalutamide (ENZ) sequential therapy may offer additional clinical benefits, particularly in improving overall survival.
- Findings support ENZ as a preferred first-line option and ABI-ENZ as a potential sequential strategy for CRPC management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...